Reduction in fatigue · people with fatigue in Guillain‐Barré syndrome
Amantadine showed no clear difference in reduction in fatigue of at least 1‐point on the Fatigue Severity… compared with placebo (low certainty).
1 finding from 1 review
OR 0.56 [0.22, 1.35]
74 participants
Low
Change in 10‐metre walking time · people with fatigue in peripheral neuropathy
1 finding from 1 review
Health‐related quality of life (physical) · people with fatigue in peripheral neuropathy
1 finding from 1 review
Participation · people with fatigue in peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (mental) · people with fatigue in peripheral neuropathy
1 finding from 1 review
Fatigue · people with fatigue in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in activity limitations · people with fatigue in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participation · people with fatigue in Guillain‐Barré syndrome
1 finding from 1 review
no estimate extracted
74 participants
Low
Health related quality of life after 12 or more weeks or more after commencement of intervention (not reported) · people with fatigue in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction in fatigue · people with fatigue in peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatigue · people with fatigue in peripheral neuropathy
1 finding from 1 review
Measures of lung capacity over the medium term (greater than 3 months but less than 1 year) · children and young males with DMD
1 finding from 1 review
Measures of lung capacity over the short term (less than 3 months) Measured by: post‐intervention TLC · people with myasthenia gravis
1 finding from 1 review
Measures of lung capacity over the short term (less than 3 months) Measured by: post‐intervention TLC · children and young males with DMD
1 finding from 1 review
Intervention not reported
Adverse effects related to the intervention · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Change in cramp frequency (cramps per night) (after 6 weeks) · older adults with lower limb muscle cramps
1 finding from 1 review
Adverse events · older adults with lower limb muscle cramps
1 finding from 1 review
Change in cramp severity (0 to 10 VAS; higher = worse pain) (after 6 weeks) · older adults with lower limb muscle cramps
1 finding from 1 review
Proportion of participants experiencing cramps · older adults with lower limb muscle cramps
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · older adults with lower limb muscle cramps
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found